Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535437) titled 'A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer' on April 10.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Memorial Sloan Kettering Cancer Center
Condition:
Non-Small Cell Lung Cancer
Intervention:
Drug: Ivonescimab
Drug: Dato-DXd
Recruitment Status: Recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: April 9, 2026
Target Sample Size: 66
Countries of Recruitment:
United States
To know more, visi...